KU14R
KU14R is a new I (3) -R antagonist, which selectively blocks the insulin secretory response to imidazolines. IC50 Value: Target: Insulin Receptor A new I (3) -R antagonist, KU14R (2 (2-ethyl 2,3-dihydro-2-benzofuranyl) -2-imidazole), which selectively blocks the insulin secretory response to imidazolines. KU14R partially attenuated responses to Imidazole-4-acetic acid-ribotide (IAA-RP) . The effects of KU14R on stimulus secretion-coupling in normal mouse islets and beta cells was compared by measuring KATP channel activity, plasma membrane potential, cytosolic calcium concentration ([Ca2+]c) and dynamic insulin secretion. In the presence of 10 mmol/l but not of 5 mmol/l glucose, KU14R (30, 100 or 300 micromol/l) was ineffective. KATP channel was blocked by KU14R (IC50 31.9 micromol/l, Hill slope -1.5) . KU14R does not act as an antagonist of either efaroxan or S22068 at an imidazoline site in vivo.
Product Specifications
CAS Number
189224-48-4
UNSPSC
12352005
Target
Insulin Receptor
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Endocrinology
Assay Protocol
https://www.medchemexpress.com/ku14r.html
Purity
98.91
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CCC1(C2=NC=CN2)OC3=CC=CC=C3C1
Molecular Formula
C13H14N2O
Molecular Weight
214.26
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
